ClinicalTrials.gg
CompletedNCT00694161Updated Jan 11, 2013Results posted

The Effects Of Fx-1006A On Transthyretin Stabilization And Clinical Outcome Measures In Patients With V122I Or Wild-Type TTR Amyloid Cardiomyopathy

A Phase 2 interventional study of Fx-1006A in Cardiomyopathy, sponsored by Pfizer. Completed at 6 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2013-01-11.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 230 studies in Cardiomyopathies with a site in United States — 56 open to participants now, 68 under way, 6 of them phase 3. Cardiomyopathies · United States.

Enrollment
74th of 132
35 · median 42
Started
2008
with 9 others
Phase 2
19 of 230
4 open now
Registered
46th of 230
by date
Lead sponsor
5 of 230
Pfizer

Among the 230 studies in Cardiomyopathies with a site in United States, this one is the 74th largest by enrollment of the 132 interventional ones that give a count, is one of 10 that started in 2008, is one of 19 in phase 2, and was the 46th registered.

Cardiomyopathies

553 studies on the registry are indexed under Cardiomyopathies; 151 are open to participants now.

Browse Cardiomyopathies studies →

Open to participants now

56 of the 230 studies in Cardiomyopathies with a site in United States are open now. Recruiting first, the newest first:

51 more — sign in →

All 56 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 115 Cardiomyopathies studies recruiting now, 70 (61%) set no upper age limit and 17 (15%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 230 studies in Cardiomyopathies with a site in United States, or all of them as a file.
02

Study summary

Open-label, multicenter, international, single-treatment study designed to determine TTR stabilization as well as Fx-1006A safety and tolerability, and its effects on clinical outcomes in patients with V122I or wild-type TTR amyloid cardiomyopathy.

The study will be conducted in two parts. Part 1 will include a six-week dosing period during which all enrolled patients will self-administer oral Fx-1006A 20 mg soft gelatin capsules once daily for six weeks. At Week 6, blood samples will be collected from each patient to determine TTR stabilization. Patients who complete the Week 6 visit will continue taking daily oral Fx 1006A 20 mg for up to a total of 12 months during Part 2 of this study. If it is determined that a patient is not stabilized at Week 6 (based on TTR stabilization data), the patient will be discontinued from the study. Safety and clinical outcomes will be evaluated during Part 2 of this study.

Two whole blood samples for pharmacodynamic assessments (TTR stabilization) and pharmacokinetic assessments (Fx-1006A concentrations as well as calculated steady-state parameters) will be collected at Baseline and Week 6. At Months 6 and 12, two whole blood samples will be collected for pharmacodynamic assessments, and four whole blood samples (two samples per time point) will be collected for pharmacokinetic assessments to be utilized in population pharmacokinetic modeling.

Echocardiography, chest x-ray, cardiac MRI, and 24-hour Holter monitoring will be conducted at Baseline, and Months 6 and 12. Six-minute walk test and quality of life utilizing the Patient Global Assessment, KCCQ, and SF-36 will be assessed at Baseline, and Months 3, 6, and 12. NYHA Classification will be assessed at Baseline, Week 6, and Months 3, 6, and 12. Serum markers of troponin I and T, and NT-pro-BNP levels will be assessed at each study visit.

Safety and tolerability will be assessed throughout the study. Vital signs, 12-lead ECG, blood and urine samples for clinical laboratory tests (serum chemistry, hematology, coagulation panel, and urinalysis), AEs, and concomitant medications (including diuretic usage) will be assessed at each study visit. Abbreviated physical examinations will be conducted at Baseline, Weeks 2 and 6, and Months 3 and 6, and a complete physical examination will be conducted at Month 12.

Clinic visits will be conducted during Screening (Days -30 to -1) and Baseline (Day 0); procedures scheduled for the Baseline visit may be conducted over a period of one week to accommodate patient scheduling. All Baseline procedures must be completed prior to the first self-administered dose on Day 1. Day 1 will be defined as administration of the first dose of study medication, which patients will self-administer at home. During treatment, clinic visits will be conducted at Week 2 (± 2 days), Week 6 (± 1 week), Month 3 (± 1 week), Month 6 (± 2 weeks), and Month 12 (± 2 weeks). Procedures scheduled for the Month 6 and 12 visits may occur over one week during the visit window to accommodate patient scheduling. Monthly telephone contacts (± 1 week of the scheduled date) will be made during months in which no clinical site visits are scheduled (Months 4, 5, 7, 8, 9, 10, and 11) for assessment of AEs and concomitant medications. A final telephone contact to assess AEs and concomitant medication usage will be made 30 days after the last dose of study medication for each patient.

Patients who discontinue from the study at any time will have a final visit performed, including all safety assessments, at the time of discontinuation. Any patient discontinuing after the Month 6 visit will also have all exploratory assessments performed.

03

Conditions studied

  • Cardiomyopathy

Browse trials for

Keywords

  • Transthyretin
  • TTR
  • ATTR
  • TTR amyloidosis
  • cardiomyopathy
  • V122I
  • wild-type TTR
  • SSA
  • Patients with V122I or wild-type TTR amyloid cardiomyopathy
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient is > 40 years-old.
  2. Patient participated in FoldRx Study Fx-001 (TRACS) OR Patient has documented TTR amyloid cardiomyopathy and Classification of I or II.

    TTR amyloid cardiomyopathy is defined as:

    1. Variant TTR amyloid cardiomyopathy as defined as: V122I genotype and presence of amyloid in cardiac tissue (as determined by congo red stain, alcin blue stain, or immunohistochemical TTR analysis), or
    2. Variant TTR amyloid cardiomyopathy as defined as: V122I genotype, evidence of cardiac involvement by echocardiography with left ventricle wall thickness > 12 mm and presence of amyloid in non-cardiac biopsy tissue (as determined by congo red stain, alcin blue stain, or immunohistochemical TTR analysis), or
    3. Wild-type TTR amyloid cardiomyopathy as defined as: normal TTR genotype and presence of TTR amyloid deposits in cardiac biopsy tissue (as determined by congo red stain and immunohistochemical TTR analysis), or
    4. Wild-type TTR amyloid cardiomyopathy as defined as: normal TTR genotype, evidence of cardiac involvement by echocardiography with left ventricle wall thickness > 12 mm and presence of TTR amyloid deposits in non-cardiac biopsy tissue (as determined by congo red stain and immunohistochemical TTR analysis).
  3. Patient's symptoms of congestive heart failure (CHF) have been optimally managed prior to baseline, as assessed by the Principal Investigator. Optimal CHF management includes stable drug regimen for ≥ 4 weeks prior to enrollment and stable dose of beta blocker for ≥ 3 months prior to enrollment.
  4. If female, patient is . If male with a female partner of , willing to use an acceptable method of for the duration of the study and for at least 3 months after the last dose of study medication.
  5. Patient is, in the opinion of the Investigator, willing and able to comply with the study medication regimen and all other study requirements

Exclusion criteria

Exclusion Criteria:

  1. Chronic use of non-protocol approved non-steroidal anti-inflammatory drugs (NSAIDs), defined as greater than 3-4 times/month. The following NSAID are allowed: acetylsalicylic acid, etodolac, ibuprofen, indomethicin, ketoprofen, nabumetone, naproxen, nimesulide, piroxicam, and sulindac.
  2. Patient has a TTR mutation other than V122I.
  3. Patient has primary or secondary amyloidosis.
  4. Patient has received prior liver or heart transplantation.
  5. Patient with positive results for surface antigen (HBsAg), anti- virus (anti-HCV), and/or (HIV).
  6. Patient has renal failure requiring dialysis.
  7. Patient has moderate or severe hepatic impairment (assessed by ).
  8. Patient has liver function test abnormalities: (ALT) and/or aspartate transaminases (AST) > 2 times (ULN) that, in the medical judgment of the Investigator, are due to reduced liver function or active liver disease.
  9. Patient has prior non-amyloid cardiac disease, such as myocardial infarction due to obstructive coronary artery disease, active non-amyloid cardiomyopathy (i.e., symptomatic left ventricular dysfunction from any cause other than amyloid), or symptomatic valvular heart disease that significantly contribute to the patient's underlying cardiac signs or symptoms.
  10. Patient has a co-morbidity anticipated to limit survival to less than 12 months.
  11. Patient received an drug/device in another clinical investigational study within 60 days before Baseline (Day 0).
  12. Patient had active alcohol or substance abuse within 60 days before Baseline (Day 0).
  13. Patient has a history of documented noncompliance.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Fx-1006A

    Drug: Fx-1006A

Interventions

  • Fx-1006A 20mg soft gelatin capsules once daily (at the same time each day) for 12 months

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Stabilized Transthyretin (TTR Tetramer) at Week 6

    TTR tetramer was assessed using a validated immunoturbidimetric assay. The Fraction of Initial (FOI) is the ratio of the measured TTR tetramer concentration after denaturation to the measured TTR tetramer concentration before denaturation. TTR tetramer stabilization is based on the difference between the on-treatment FOI and the baseline FOI expressed as a percentage of the baseline FOI.

    Time frame: Week 6

Secondary outcomes

  1. Percentage of Participants With Stabilized Transthyretin (TTR Tetramer) at Month 6 and 12

    TTR tetramer was assessed using a validated immunoturbidimetric assay. The Fraction of Initial (FOI) is the ratio of the measured TTR tetramer concentration after denaturation to the measured TTR tetramer concentration before denaturation. TTR tetramer stabilization is based on the difference between the on-treatment FOI and the baseline FOI expressed as a percentage of the baseline FOI.

    Time frame: Month 6, Month 12

Other outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (AEs)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent are events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state.

    Time frame: Baseline up to 30 days after the last dose

  2. Number of Participants With Greater Than or Equal to (>=) Grade 3 Treatment-Emergent AEs

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent are events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state. On the basis of intensity, grade 3 was referred as severe, grade 4 as life-threatening and grade 5 as death.

    Time frame: Baseline up to 30 days after the last dose

  3. Number of Participants With Clinically Significant Treatment-Emergent Echocardiography (ECHO) Findings

    ECHO:investigator assessed test to assess cardiac function.ECHO abnormality criteria:any/valvular abnormality,pericardial effusion,abnormal regional wall motion,inferior vena cava respiratory variation,posterior left ventricular wall/septal thickness\>=13 millimeter(mm),right ventricular thickness\>=7mm,ejection fraction \<50%, ratio of early (E) diastolic transmitral flow and atrial(A) contraction velocity (E/A)\>=2, ratio of 'E'to lateral/septal mitral annular velocity (e') (E/e'prime lateral\>15, E/e'prime septal\>15), E deceleration time\<=150 millisecond(msec),Isovolumic relaxation time\<=70msec.

    Time frame: Baseline up to Month 12

  4. Number of Participants Discontinuing From The Study Due to Clinically Significant Clinical or Laboratory Adverse Events (AEs)

    Time frame: Baseline up to Month 12

  5. Change From Baseline in Echocardiographic (ECHO) Parameters at Month 6 and 12

    Echocardiography was used to measure interventricular septal thickness (IVST), posterior left ventricular wall thickness (PLVWT), right ventricular wall thickness (RVWT), left atrial diameter (LAD): anterior-posterior (ant-post), medio-lateral, superior-inferior (sup-inf) and left ventricular end diastolic diameter (LVEDD).

    Time frame: Baseline, Month 6, Month 12

  6. Change From Baseline in Left Ventricular Mass (LVM) at Month 6 and 12

    LVM was defined as increase in the mass of left ventricle, estimated by echocardiography. Increased LVM was associated with cardiovascular morbidity and mortality.

    Time frame: Baseline, Month 6, Month 12

  7. Change From Baseline in Left Ventricular Ejection Fraction at Month 6 and 12

    Left ventricular ejection fraction (LVEF) was the fraction of the end-diastolic volume (EDV) that is ejected out of left ventricle with each contraction, estimated by echocardiography. EDV is the volume of blood within a ventricle immediately before a contraction.

    Time frame: Baseline, Month 6, Month 12

  8. Change From Baseline in Doppler Data: E/A and E/e' Ratio at Month 6 and 12

    Doppler echocardiography was a procedure which used ultrasound technology to examine the heart. Ratio of early (E) diastolic transmitral flow velocity and atrial (A) contraction velocity (E/A) and ratio of the early (E) diastolic transmitral flow velocity to the mitral annular velocity (e') (E/e') were estimated.

    Time frame: Baseline, Month 6, Month 12

  9. Change From Baseline in Doppler Data: Mitral Deceleration Time at Month 6 and 12

    Doppler echocardiography was a procedure which used ultrasound technology to examine the heart. The mitral deceleration time was the time taken from the maximum E wave to baseline. E wave arises due to early diastolic filling.

    Time frame: Baseline, Month 6, Month 12

  10. Change From Baseline in Tissue Doppler- Septal and Lateral Velocity at Month 6 and 12

    Tissue Doppler used doppler principles to measure the annular velocities at the lateral and septal areas of the mitral annulus. s': systolic velocity during ejection, e': early diastolic mitral annular velocity, a': late diastolic mitral annular velocity.

    Time frame: Baseline, Month 6, Month 12

  11. Change From Baseline in Pericardial Effusion at Month 6 and 12

    Pericardial effusion was the presence of an abnormal amount of fluid in the pericardial cavity, as determined by echocardiography.

    Time frame: Baseline, Month 6, Month 12

  12. Number of Participants With Change From Baseline in Valvular Abnormalities at Month 6 and 12

    Valvular abnormalities were those abnormalities (thickening or regurgitation) that involved one or more valves of the heart, determined by echocardiography.

    Time frame: Baseline, Month 6, Month 12

  13. Change From Baseline in Left Ventricular Anteroseptal, Left Ventricular Inferolateral Wall Thickness and Right Ventricular End Diastolic Free Wall Thickness at Month 6 and 12

    Cardiac Magnetic Resonance Imaging (MRI) was done to measure the thickness of left ventricular anteroseptal (LVAS) wall, left ventricular inferolateral (LVIL) wall and right ventricular end diastolic free (RVEDF) wall.

    Time frame: Baseline, Month 6, Month 12

  14. Change From Baseline in Left Ventricular Mass, Mass of Left Ventricular Myocardium With Amyloidosis, Mass of Left Ventricular Myocardium With Fibrosis/Scar and Right Ventricular End Diastolic Mass at Month 6 and 12

    Cardiac MRI was done to measure LVM, mass of left ventricular (LV) myocardium with amyloidosis, mass of LV myocardium with fibrosis/scar and right ventricular end diastolic mass (RVEDM).

    Time frame: Baseline, Month 6, Month 12

  15. Change From Baseline in Left Ventricle End Diastolic Volume, Left Ventricle End Systolic Volume, Left Ventricle Stroke Volume, Right Ventricle End Diastolic Volume, Right Ventricle End Systolic Volume, Right Ventricle Stroke Volume at Month 6 and 12.

    Cardiac MRI was done to measure left ventricle end diastolic volume (LVEDV), left ventricle end systolic volume (LVESV), left ventricle stroke volume (LVSV), right ventricle end diastolic volume (RVEDV), right ventricle end systolic volume (RVESV) and right ventricle stroke volume (RVSV).

    Time frame: Baseline, Month 6, Month 12

  16. Change From Baseline in Left Ventricular Ejection Fraction and Right Ventricular Ejection Fraction at Month 6 and 12

    Cardiac MRI was done to measure: left ventricular ejection fraction (LVEF) was the fraction of the EDV that is ejected out of left ventricle with each contraction and right ventricular ejection fraction (RVEF) was the fraction of the EDV that is ejected out of right ventricle with each contraction. EDV is the volume of blood within a ventricle immediately before a contraction.

    Time frame: Baseline, Month 6, Month 12

  17. Change From Baseline in Left Ventricular Cardiac Output and Right Ventricular Cardiac Output at Month 6 and 12

    Cardiac MRI was done to measure cardiac output, which was the volume of blood being pumped by the heart, in particular by the left or right ventricle in the time interval of one minute.

    Time frame: Baseline, Month 6, Month 12

  18. Change From Baseline in Percentage of Left Ventricular Myocardial Mass With Amyloidosis and Left Ventricular Myocardial Mass With Fibrosis/Scar at Month 6 and 12

    Cardiac MRI was done to measure percentage of LV myocardial mass with amyloidosis and LV myocardial mass with fibrosis/scar. LV myocardial mass with amyloidosis or fibrosis/scar was calculated from the product of the myocardial volume and specific gravity of heart muscle, in participants with amyloidosis or fibrosis/scar, respectively.

    Time frame: Baseline, Month 6, Month 12

  19. Change From Baseline in 4 Chamber Interatrial Septal Thickness at Month 6 and 12

    Cardiac MRI was done to measure interatrial septal thickness in the 4 chamber view.

    Time frame: Baseline, Month 6, Month 12

  20. Change From Baseline in 4 Chamber Left Atrial Dimension and 4 Chamber Right Atrial Dimension at Month 6 and 12

    Cardiac MRI was done to measure the left and right atrial dimensions which have diagnostic and prognostic significance in cardiology, in the 4 chamber view.

    Time frame: Baseline, Month 6, Month 12

  21. Number of Participants With Atrial Fibrillation/Flutter, Atrial Tachycardia, Non-Sustained Ventricular Tachycardia (NSVT) Beats), Sustained Ventricular Tachycardia (SVT), Sinus Pause at Month 6 and 12

    Holter monitor was a machine that recorded the heart rhythms. Holter monitoring abnormalities of atrial fibrillation/flutter (rapid, irregular heart rhythm), atrial tachycardia (rapid cardiac rate), non-sustained ventricular tachycardia (NSVT)\<30 beats, sustained ventricular tachycardia (SVT) \>=30 beats and sinus pause (transient interruption in the sinus rhythm) were recorded.

    Time frame: Baseline, Month 6, Month 12

  22. 24-Hour Average Heart Rate and Maximium/Minimum Heart Rate

    Holter monitor was a machine that recorded the heart rhythms. 24-hour average heart rate and maximium/minimum heart rate was recorded using Holter monitoring.

    Time frame: Baseline, Month 6, Month 12

  23. Number of Participants With Complete Heart Block

    Complete heart block is the third-degree atrioventricular block in which the impulse generated in the sinoatrial node in the atrium does not propagate to the ventricles.

    Time frame: Baseline, Month 6, Month 12

  24. Heart Rate Variability (HRV)- Standard Deviation (SD) Parameters

    Holter monitor was a machine that recorded the heart rhythms. HRV time-domain indices were summarized for root-mean-square of successive differences \[RMS SD\] of the R-R intervals (R-R is the interval between successive Rs in the ECG wave) between normal beats (NN), magid standard deviation (Magid SD) of normal to normal R-R intervals and Kleiger standard deviation of normal to normal R-R intervals (Kleiger SD). The term 'NN' is used in place of 'R-R' when the processed beats are normal beats.

    Time frame: Baseline, Month 6, Month 12

  25. Heart Rate Variability- Percentage of Successive R-R Intervals With Greater Than 50 Msec Difference Between Normal Beats (pNN50)

    Holter monitor was a machine that recorded the heart rhythms. The term 'NN' was used in place of 'R-R' when the processed beats are normal beats. The percentage of successive R-R intervals with greater than 50 msec difference between normal beats was derived by dividing NN50 by the total number of NN intervals (pNN50), where NN50 was the number of interval differences of successive NN intervals greater than 50 msec.

    Time frame: Baseline, Month 6, Month 12

  26. Number of Participants With Change From Baseline in New York Heart Association (NYHA) Classification at Week 6, Month 3, 6 and 12

    NYHA: classified as 'class I' (participants with cardiac disease but without resulting limitations of physical activity), 'class II' (participants with cardiac disease resulting in slight limitation of physical activity), 'class III' (participants with cardiac disease resulting in marked limitation of physical activity), 'class IV' (participants with cardiac disease resulting in inability to carry on any physical activity without discomfort). Participants with change from baseline were classified as 'improved' (positive change), 'no change' or 'worsened' (negative change).

    Time frame: Baseline, Week 6, Month 3, Month 6, Month 12

  27. Cardiothoracic (CT) Ratio

    Cardiothoracic ratio was defined as the transverse diameter of the heart, compared with that of the thoracic cage, used to help determine enlargement of the heart.

    Time frame: Baseline, Month 6, Month 12

  28. Number of Participants With Increased Interstitial Markings and Pleural Effusions

    Chest x-ray was done to record the presence of increased interstitial markings (a large number of interstitial markings was indicative of abnormality in the lung) and pleural effusion, which was defined as accumulation of fluid between the layers of tissue that line the lungs and chest cavity.

    Time frame: Baseline, Month 6, Month 12

  29. Number of Participants With Change in Patient Global Assessment (PtGA) at Month 3, 6 and 12

    Participant's overall quality of life was measured by the PtGA. At baseline participants answered to question: "in general, how do you feel today?" - on a 5-point scale from '1' (excellent) to '5' (poor). At each follow-up visit, participant's answered to question: "How do you feel today as compared to when we talked with you at your last clinic visit for this study?" on a 7-point scale- '1' markedly improved, '2' moderately improved, '3' mildly improved, '4' unchanged, '5' mildly worsened, '6' moderately worsened, '7' markedly worsened.

    Time frame: Baseline, Month 3, Month 6, Month 12

  30. Change From Baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) Score at Month 3, 6 and 12

    KCCQ was a 23-item heart failure specific questionnaire quantified in to following 10 summary scores: physical limitation, symptom frequency, symptom severity, and symptom stability, total symptoms, quality of life, social interference, self-efficacy, overall summary and clinical summary. Total score ranged from 0 to 100, where higher scores indicated better functioning, fewer symptoms, and better disease specific quality of life. Summary scores were scaled to range from 0 to 100, with higher scores representing greater disability.

    Time frame: Baseline, Month 3, Month 6, Month 12

  31. Change From Baseline in the Short Form 36 (SF-36) at Month 3, 6 and 12

    SF-36 was standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. Scores for the 8 domains range from 0-100, where higher scores were better (100=highest level of functioning) and reported as 2 summary scores; Mental Component Score (MCS) and Physical Component Score (PCS). The score for a section was an average of the individual question scores, which were scaled 0-100, where higher scores were better.

    Time frame: Baseline, Month 3, Month 6, Month 12

  32. Change From Baseline in Troponin I and Troponin T at Week 2, 6, Month 3, 6 and 12

    Troponin I and troponin T were the cardiac markers. Troponin I and troponin T were part of the troponin complex, where troponin I was bound to actin in thin myofilaments and troponin T was bound to tropomyosin. Higher level of these markers was indicative of heart damage.

    Time frame: Baseline, Week 2, Week 6, Month 3, Month 6, Month 12

  33. Change From Baseline in N-Terminal Prohormone Brain Natriuretic Peptide(NT-proBNP) Levels at Week 2, 6, Month 3, 6 and 12

    NT-proBNP was a cardiac marker which had the prognostic value for participants with heart failure or left ventricular dysfunction. Higher level of the marker was indicative of heart damage.

    Time frame: Baseline, Week 2, Week 6, Month 3, Month 6, Month 12

  34. Change From Baseline in 6-Minute Walk Test (6MWT) at Month 3, 6 and 12

    6MWT was used to assess the distance that a participant could walk in 6 minutes. Participants were asked to perform the test at a pace that was comfortable to them, with as many breaks as they needed. Continuous pulse oximetry was conducted during the test for safety.. The distance walked in 6 minutes was categorized as: Level 1: \<300 meter, Level 2: 300-374.9 meter, Level 3: 375-449.9 meter, Level 4: \>=450 meter.

    Time frame: Baseline, Month 3, Month 6, Month 12

07

Results

Posted Dec 18, 2012
Limitations and caveats
Results for Holter monitoring parameters, increased interstitial markings, pleural effusions, PtGA and cardiothoracic ratio are presented as absolute values at specified time points and not as change from baseline as planned.

Participant flow

Part 1 (up to Week 6)
Participant flow — Part 1 (up to Week 6)
MilestoneTafamidis
Started35
Completed35
Not completed0
Part 2 (After Week 6 up to Month 12)
Participant flow — Part 2 (After Week 6 up to Month 12)
MilestoneTafamidis
Started35
Completed32
Not completed3
Withdrew: Adverse event1
Withdrew: Physician decision1
Withdrew: Death1

Outcome measures

PrimaryPercentage of Participants With Stabilized Transthyretin (TTR Tetramer) at Week 6

TTR tetramer was assessed using a validated immunoturbidimetric assay. The Fraction of Initial (FOI) is the ratio of the measured TTR tetramer concentration after denaturation to the measured TTR tetramer concentration before denaturation. TTR tetramer stabilization is based on the difference between the on-treatment FOI and the baseline FOI expressed as a percentage of the baseline FOI.

Time frame:
Week 6
Reported as:
Number · Percentage of participants
Percentage of Participants With Stabilized Transthyretin (TTR Tetramer) at Week 6
Percentage of participantsTafamidis
Percentage of Participants With Stabilized Transthyretin (TTR Tetramer) at Week 697.1 (85.1 to 99.9)
SecondaryPercentage of Participants With Stabilized Transthyretin (TTR Tetramer) at Month 6 and 12

TTR tetramer was assessed using a validated immunoturbidimetric assay. The Fraction of Initial (FOI) is the ratio of the measured TTR tetramer concentration after denaturation to the measured TTR tetramer concentration before denaturation. TTR tetramer stabilization is based on the difference between the on-treatment FOI and the baseline FOI expressed as a percentage of the baseline FOI.

Time frame:
Month 6, Month 12
Reported as:
Number · Percentage of participants
Percentage of Participants With Stabilized Transthyretin (TTR Tetramer) at Month 6 and 12
Percentage of participantsTafamidis
Month 688.2 (72.5 to 96.7)
Month 1287.5 (71.0 to 96.5)
Other pre-specifiedNumber of Participants With Treatment-Emergent Adverse Events (AEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent are events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state.

Time frame:
Baseline up to 30 days after the last dose
Reported as:
Number · Participants
Number of Participants With Treatment-Emergent Adverse Events (AEs)
ParticipantsTafamidis
Number of Participants With Treatment-Emergent Adverse Events (AEs)35
Other pre-specifiedNumber of Participants With Greater Than or Equal to (>=) Grade 3 Treatment-Emergent AEs

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent are events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state. On the basis of intensity, grade 3 was referred as severe, grade 4 as life-threatening and grade 5 as death.

Time frame:
Baseline up to 30 days after the last dose
Reported as:
Number · Participants
Number of Participants With Greater Than or Equal to (>=) Grade 3 Treatment-Emergent AEs
ParticipantsTafamidis
Grade 3 (severe)18
Grade 4 (life-threatening)1
Grade 5 (death)2
Other pre-specifiedNumber of Participants With Clinically Significant Treatment-Emergent Echocardiography (ECHO) Findings

ECHO:investigator assessed test to assess cardiac function.ECHO abnormality criteria:any/valvular abnormality,pericardial effusion,abnormal regional wall motion,inferior vena cava respiratory variation,posterior left ventricular wall/septal thickness\>=13 millimeter(mm),right ventricular thickness\>=7mm,ejection fraction \<50%, ratio of early (E) diastolic transmitral flow and atrial(A) contraction velocity (E/A)\>=2, ratio of 'E'to lateral/septal mitral annular velocity (e') (E/e'prime lateral\>15, E/e'prime septal\>15), E deceleration time\<=150 millisecond(msec),Isovolumic relaxation time\<=70msec.

Time frame:
Baseline up to Month 12
Reported as:
Number · Participants
Number of Participants With Clinically Significant Treatment-Emergent Echocardiography (ECHO) Findings
ParticipantsTafamidis
Any ECHO abnormalities (n=34)31
Pericardial effusion (n=28)6
Valvular abnormalities- thickening (n=4)4
Valvular abnormalities- regurgitation (n=7)6
Abnormal regional wall motion (n=19)10
Inferior vena cava respiratory variation (n=14)7
Left ventricular posterior wall thickness (n=0)NA
Left ventricular septal thickness (n=0)NA
Right ventricular thickness (n=7)6
E/A ratio (n=8)4
E/e' prime lateral (n=13)5
E/e' prime septal (n=6)5
Ejection fraction (n=18)11
E deceleration time (n=16)8
Isovolumic relaxation time (n=16)4
Other pre-specifiedNumber of Participants Discontinuing From The Study Due to Clinically Significant Clinical or Laboratory Adverse Events (AEs)
Time frame:
Baseline up to Month 12
Reported as:
Number · Participants
Number of Participants Discontinuing From The Study Due to Clinically Significant Clinical or Laboratory Adverse Events (AEs)
ParticipantsTafamidis
Number of Participants Discontinuing From The Study Due to Clinically Significant Clinical or Laboratory Adverse Events (AEs)1
Other pre-specifiedChange From Baseline in Echocardiographic (ECHO) Parameters at Month 6 and 12

Echocardiography was used to measure interventricular septal thickness (IVST), posterior left ventricular wall thickness (PLVWT), right ventricular wall thickness (RVWT), left atrial diameter (LAD): anterior-posterior (ant-post), medio-lateral, superior-inferior (sup-inf) and left ventricular end diastolic diameter (LVEDD).

Time frame:
Baseline, Month 6, Month 12
Reported as:
Mean · millimeter (mm)
Change From Baseline in Echocardiographic (ECHO) Parameters at Month 6 and 12
millimeter (mm)Tafamidis
IVST: Baseline (n=34)20.71 ± 3.58
IVST: Change at Month 6 (n=33)-0.64 ± 2.41
IVST: Change at Month 12 (n=30)0.87 ± 2.52
PLVWT: Baseline (n=34)20.20 ± 3.37
PLVWT: Change at Month 6 (n=33)-0.50 ± 3.83
PLVWT: Change at Month 12 (n=30)-0.00 ± 2.11
RVWT: Baseline (n=27)9.21 ± 2.34
RVWT: Change at Month 6 (n=21)-0.47 ± 2.47
RVWT: Change at Month 12 (n=20)0.26 ± 2.25
LAD (ant-post): Baseline (n=34)45.00 ± 6.14
LAD (ant-post): Change at Month 6 (n=33)-0.40 ± 4.33
LAD (ant-post): Change at Month 12 (n=30)-0.30 ± 4.19
LAD (medio-lateral): Baseline (n=34)44.10 ± 5.56
LAD (medio-lateral): Change at Month 6 (n=32)0.70 ± 5.17
LAD (medio-lateral): Change at Month 12 (n=30)-0.90 ± 6.41
LAD (sup-inf): Baseline (n=34)61.50 ± 8.43
LAD (sup-inf): Change at Month 6 (n=32)3.00 ± 5.90
LAD (sup-inf): Change at Month 12 (n=30)0.80 ± 6.29
LVEDD: Baseline (n=34)37.94 ± 5.19
LVEDD: Change at Month 6 (n=33)0.45 ± 3.49
LVEDD: Change at Month 12 (n=30)0.10 ± 3.41
Other pre-specifiedChange From Baseline in Left Ventricular Mass (LVM) at Month 6 and 12

LVM was defined as increase in the mass of left ventricle, estimated by echocardiography. Increased LVM was associated with cardiovascular morbidity and mortality.

Time frame:
Baseline, Month 6, Month 12
Reported as:
Mean · Gram
Change From Baseline in Left Ventricular Mass (LVM) at Month 6 and 12
GramTafamidis
Baseline (n=34)372.50 ± 123.96
Change at Month 6 (n=33)-19.76 ± 54.38
Change at Month 12 (n=30)13.73 ± 77.12
Other pre-specifiedChange From Baseline in Left Ventricular Ejection Fraction at Month 6 and 12

Left ventricular ejection fraction (LVEF) was the fraction of the end-diastolic volume (EDV) that is ejected out of left ventricle with each contraction, estimated by echocardiography. EDV is the volume of blood within a ventricle immediately before a contraction.

Time frame:
Baseline, Month 6, Month 12
Reported as:
Mean · Percentage of EDV
Change From Baseline in Left Ventricular Ejection Fraction at Month 6 and 12
Percentage of EDVTafamidis
Baseline (n=34)46.8 ± 14.1
Change at Month 6 (n=33)-0.4 ± 10.3
Change at Month 12 (n=30)-3.7 ± 10.4
Other pre-specifiedChange From Baseline in Doppler Data: E/A and E/e' Ratio at Month 6 and 12

Doppler echocardiography was a procedure which used ultrasound technology to examine the heart. Ratio of early (E) diastolic transmitral flow velocity and atrial (A) contraction velocity (E/A) and ratio of the early (E) diastolic transmitral flow velocity to the mitral annular velocity (e') (E/e') were estimated.

Time frame:
Baseline, Month 6, Month 12
Reported as:
Mean · Ratio
Change From Baseline in Doppler Data: E/A and E/e' Ratio at Month 6 and 12
RatioTafamidis
E/A ratio: Baseline (n=19)2.516 ± 1.084
E/A ratio: Change at Month 6 (n=12)0.425 ± 1.117
E/A ratio: Change at Month 12 (n=9)0.544 ± 0.575
E/e' ratio: Baseline (n=26)16.240 ± 9.089
E/e' ratio: Change at Month 6 (n=15)2.217 ± 3.166
E/e' ratio: Change at Month 12 (n=14)-0.717 ± 5.681
Other pre-specifiedChange From Baseline in Doppler Data: Mitral Deceleration Time at Month 6 and 12

Doppler echocardiography was a procedure which used ultrasound technology to examine the heart. The mitral deceleration time was the time taken from the maximum E wave to baseline. E wave arises due to early diastolic filling.

Time frame:
Baseline, Month 6, Month 12
Reported as:
Mean · msec
Change From Baseline in Doppler Data: Mitral Deceleration Time at Month 6 and 12
msecTafamidis
Baseline (n=33)152.9 ± 35.3
Change at Month 6 (n=27)1.0 ± 37.5
Change at Month 12 (n=27)-7.1 ± 32.6
Other pre-specifiedChange From Baseline in Tissue Doppler- Septal and Lateral Velocity at Month 6 and 12

Tissue Doppler used doppler principles to measure the annular velocities at the lateral and septal areas of the mitral annulus. s': systolic velocity during ejection, e': early diastolic mitral annular velocity, a': late diastolic mitral annular velocity.

Time frame:
Baseline, Month 6, Month 12
Reported as:
Mean · centimeter/second (cm/sec)
Change From Baseline in Tissue Doppler- Septal and Lateral Velocity at Month 6 and 12
centimeter/second (cm/sec)Tafamidis
Septal s': Baseline (n=23)3.70 ± 1.31
Septal s': Change at Month 6 (n=16)-0.57 ± 0.73
Septal s': Change at Month 12 (n=14)-0.69 ± 0.77
Septal e': Baseline (n=23)3.67 ± 1.60
Septal e': Change at Month 6 (n=17)-0.09 ± 1.12
Septal e': Change at Month 12 (n=14)-0.33 ± 1.32
Septal a': Baseline (n=16)2.51 ± 1.60
Septal a': Change at Month 6 (n=6)-0.40 ± 0.43
Septal a': Change at Month 12 (n=6)-0.42 ± 0.72
Lateral s': Baseline (n=24)4.53 ± 1.59
Lateral s': Change at Month 6 (n=14)-0.50 ± 1.16
Lateral s': Change at Month 12 (n=13)-0.73 ± 1.22
Lateral e': Baseline (n=26)5.09 ± 2.00
Lateral e': Change at Month 6 (n=16)-0.76 ± 0.80
Lateral e': Change at Month 12 (n=14)0.05 ± 0.88
Lateral a': Baseline (n=17)3.16 ± 1.94
Lateral a': Change at Month 6 (n=7)-0.41 ± 0.60
Lateral a': Change at Month 12 (n=9)0.06 ± 1.03
Other pre-specifiedChange From Baseline in Pericardial Effusion at Month 6 and 12

Pericardial effusion was the presence of an abnormal amount of fluid in the pericardial cavity, as determined by echocardiography.

Time frame:
Baseline, Month 6, Month 12

No measurements were reported for this outcome.

Other pre-specifiedNumber of Participants With Change From Baseline in Valvular Abnormalities at Month 6 and 12

Valvular abnormalities were those abnormalities (thickening or regurgitation) that involved one or more valves of the heart, determined by echocardiography.

Time frame:
Baseline, Month 6, Month 12

No measurements were reported for this outcome.

Other pre-specifiedChange From Baseline in Left Ventricular Anteroseptal, Left Ventricular Inferolateral Wall Thickness and Right Ventricular End Diastolic Free Wall Thickness at Month 6 and 12

Cardiac Magnetic Resonance Imaging (MRI) was done to measure the thickness of left ventricular anteroseptal (LVAS) wall, left ventricular inferolateral (LVIL) wall and right ventricular end diastolic free (RVEDF) wall.

Time frame:
Baseline, Month 6, Month 12
Reported as:
Mean · mm
Change From Baseline in Left Ventricular Anteroseptal, Left Ventricular Inferolateral Wall Thickness and Right Ventricular End Diastolic Free Wall Thickness at Month 6 and 12
mmTafamidis
LVAS wall thickness: Baseline (n=18)15.808 ± 3.603
LVAS wall thickness: Change at Month 6 (n=18)0.810 ± 3.447
LVAS wall thickness: Change at Month 12 (n=15)0.813 ± 3.099
LVIL wall thickness: Baseline (n=18)15.405 ± 4.616
LVIL wall thickness: Change at Month 6 (n=18)-1.472 ± 4.333
LVIL wall thickness: Change at Month 12 (n=15)1.182 ± 4.782
RVEDF wall thickness: Baseline (n=17)10.871 ± 14.001
RVEDF wall thickness: Change at Month 6 (n=17)-4.501 ± 14.734
RVEDF wall thickness: Change at Month 12 (n=15)-1.577 ± 4.722
Other pre-specifiedChange From Baseline in Left Ventricular Mass, Mass of Left Ventricular Myocardium With Amyloidosis, Mass of Left Ventricular Myocardium With Fibrosis/Scar and Right Ventricular End Diastolic Mass at Month 6 and 12

Cardiac MRI was done to measure LVM, mass of left ventricular (LV) myocardium with amyloidosis, mass of LV myocardium with fibrosis/scar and right ventricular end diastolic mass (RVEDM).

Time frame:
Baseline, Month 6, Month 12
Reported as:
Mean · Gram
Change From Baseline in Left Ventricular Mass, Mass of Left Ventricular Myocardium With Amyloidosis, Mass of Left Ventricular Myocardium With Fibrosis/Scar and Right Ventricular End Diastolic Mass at Month 6 and 12
GramTafamidis
LVM: Baseline (n=18)221.599 ± 63.680
LVM: Change at Month 6 (n=18)0.557 ± 24.901
LVM: Change at Month 12 (n=15)0.119 ± 20.027
LV Amyloidosis: Baseline (n=15)63.963 ± 25.614
LV Amyloidosis : Change at Month 6 (n=14)-13.854 ± 23.921
LV Amyloidosis: Change at Month 12 (n=9)-4.346 ± 38.364
LV Fibrosis/Scar: Baseline (n=15)87.746 ± 60.297
LV Fibrosis/Scar: Change at Month 6 (n=14)-30.496 ± 52.176
LV Fibrosis/Scar: Change at Month 12 (n=9)-20.238 ± 64.487
RVEDM: Baseline (n=18)65.999 ± 20.296
RVEDM: Change at Month 6 (n=18)-4.377 ± 20.648
RVEDM: Change at Month 12 (n=15)0.215 ± 18.038
Other pre-specifiedChange From Baseline in Left Ventricle End Diastolic Volume, Left Ventricle End Systolic Volume, Left Ventricle Stroke Volume, Right Ventricle End Diastolic Volume, Right Ventricle End Systolic Volume, Right Ventricle Stroke Volume at Month 6 and 12.

Cardiac MRI was done to measure left ventricle end diastolic volume (LVEDV), left ventricle end systolic volume (LVESV), left ventricle stroke volume (LVSV), right ventricle end diastolic volume (RVEDV), right ventricle end systolic volume (RVESV) and right ventricle stroke volume (RVSV).

Time frame:
Baseline, Month 6, Month 12
Reported as:
Mean · mL
Change From Baseline in Left Ventricle End Diastolic Volume, Left Ventricle End Systolic Volume, Left Ventricle Stroke Volume, Right Ventricle End Diastolic Volume, Right Ventricle End Systolic Volume, Right Ventricle Stroke Volume at Month 6 and 12.
mLTafamidis
LVEDV: Baseline (n=18)166.673 ± 40.417
LVEDV: Change at Month 6 (n=18)-0.922 ± 21.164
LVEDV: Change at Month 12 (n=15)-1.606 ± 20.323
LVESV: Baseline (n=18)84.651 ± 29.271
LVESV: Change at Month 6 (n=18)3.727 ± 20.963
LVESV: Change at Month 12 (n=15)6.479 ± 16.810
LVSV: Baseline (n=18)82.022 ± 19.866
LVSV: Change at Month 6 (n=18)-4.651 ± 21.391
LVSV: Change at Month 12 (n=15)-8.083 ± 15.614
RVEDV: Baseline (n=18)175.124 ± 67.977
RVEDV: Change at Month 6 (n=18)-4.836 ± 37.879
RVEDV: Change at Month 12 (n=15)19.540 ± 39.413
RVESV: Baseline (n=18)104.662 ± 48.775
RVESV: Change at Month 6 (n=18)-1.727 ± 21.438
RVESV: Change at Month 12 (n=15)26.250 ± 30.858
RVSV: Baseline (n=18)70.478 ± 26.364
RVSV: Change at Month 6 (n=18)-3.125 ± 26.125
RVSV: Change at Month 12 (n=15)-6.730 ± 33.975
Other pre-specifiedChange From Baseline in Left Ventricular Ejection Fraction and Right Ventricular Ejection Fraction at Month 6 and 12

Cardiac MRI was done to measure: left ventricular ejection fraction (LVEF) was the fraction of the EDV that is ejected out of left ventricle with each contraction and right ventricular ejection fraction (RVEF) was the fraction of the EDV that is ejected out of right ventricle with each contraction. EDV is the volume of blood within a ventricle immediately before a contraction.

Time frame:
Baseline, Month 6, Month 12
Reported as:
Mean · Percentage of EDV
Change From Baseline in Left Ventricular Ejection Fraction and Right Ventricular Ejection Fraction at Month 6 and 12
Percentage of EDVTafamidis
LVEF: Baseline (n=18)50.176 ± 9.183
LVEF: Change at Month 6 (n=18)-2.713 ± 13.362
LVEF: Change at Month 12 (n=14)-3.511 ± 9.063
RVEF: Baseline (n=18)42.323 ± 11.949
RVEF: Change at Month 6 (n=18)-1.756 ± 10.381
RVEF: Change at Month 12 (n=15)-7.381 ± 12.040
Other pre-specifiedChange From Baseline in Left Ventricular Cardiac Output and Right Ventricular Cardiac Output at Month 6 and 12

Cardiac MRI was done to measure cardiac output, which was the volume of blood being pumped by the heart, in particular by the left or right ventricle in the time interval of one minute.

Time frame:
Baseline, Month 6, Month 12

No measurements were reported for this outcome.

Other pre-specifiedChange From Baseline in Percentage of Left Ventricular Myocardial Mass With Amyloidosis and Left Ventricular Myocardial Mass With Fibrosis/Scar at Month 6 and 12

Cardiac MRI was done to measure percentage of LV myocardial mass with amyloidosis and LV myocardial mass with fibrosis/scar. LV myocardial mass with amyloidosis or fibrosis/scar was calculated from the product of the myocardial volume and specific gravity of heart muscle, in participants with amyloidosis or fibrosis/scar, respectively.

Time frame:
Baseline, Month 6, Month 12
Reported as:
Mean · Percentage of LVM
Change From Baseline in Percentage of Left Ventricular Myocardial Mass With Amyloidosis and Left Ventricular Myocardial Mass With Fibrosis/Scar at Month 6 and 12
Percentage of LVMTafamidis
LV Amyloidosis: Baseline (n=15)29.069 ± 11.111
LV Amyloidosis: Change at Month 6 (n=14)-8.200 ± 14.115
LV Amyloidosis: Change at Month 12 (n=9)-7.017 ± 13.660
LV Fibrosis/Scar: Baseline (n=15)36.513 ± 17.789
LV Fibrosis/Scar: Change at Month 6 (n=14)-10.126 ± 26.397
LV Fibrosis/Scar: Change at Month 12 (n=9)-8.268 ± 24.884
Other pre-specifiedChange From Baseline in 4 Chamber Interatrial Septal Thickness at Month 6 and 12

Cardiac MRI was done to measure interatrial septal thickness in the 4 chamber view.

Time frame:
Baseline, Month 6, Month 12

No measurements were reported for this outcome.

Other pre-specifiedChange From Baseline in 4 Chamber Left Atrial Dimension and 4 Chamber Right Atrial Dimension at Month 6 and 12

Cardiac MRI was done to measure the left and right atrial dimensions which have diagnostic and prognostic significance in cardiology, in the 4 chamber view.

Time frame:
Baseline, Month 6, Month 12

No measurements were reported for this outcome.

Other pre-specifiedNumber of Participants With Atrial Fibrillation/Flutter, Atrial Tachycardia, Non-Sustained Ventricular Tachycardia (NSVT) Beats), Sustained Ventricular Tachycardia (SVT), Sinus Pause at Month 6 and 12

Holter monitor was a machine that recorded the heart rhythms. Holter monitoring abnormalities of atrial fibrillation/flutter (rapid, irregular heart rhythm), atrial tachycardia (rapid cardiac rate), non-sustained ventricular tachycardia (NSVT)\<30 beats, sustained ventricular tachycardia (SVT) \>=30 beats and sinus pause (transient interruption in the sinus rhythm) were recorded.

Time frame:
Baseline, Month 6, Month 12
Reported as:
Number · Participants
Number of Participants With Atrial Fibrillation/Flutter, Atrial Tachycardia, Non-Sustained Ventricular Tachycardia (NSVT) Beats), Sustained Ventricular Tachycardia (SVT), Sinus Pause at Month 6 and 12
ParticipantsTafamidis
Atrial fibrillation/flutter: Baseline (n=33)6
Atrial fibrillation/flutter: Month 6 (n=27)9
Atrial fibrillation/flutter: Month 12 (n=22)9
Atrial tachycardia: Baseline (n=34)14
Atrial tachycardia: Month 6 (n=20)0
Atrial tachycardia: Month 12 (n=17)0
NSVT (<30 beats): Baseline (n=34)20
NSVT (<30 beats): Month 6 (n=13)3
NSVT (<30 beats): Month 12 (n=12)5
SVT (>= 30 beats): Baseline (n=34)0
SVT (>= 30 beats): Month 6 (n=33)0
SVT (>= 30 beats): Month 12 (n=30)1
Sinus pause: Baseline (n=34)2
Sinus pause: Month 6 (n=31)4
Sinus pause: Month 12 (n=28)5
Other pre-specified24-Hour Average Heart Rate and Maximium/Minimum Heart Rate

Holter monitor was a machine that recorded the heart rhythms. 24-hour average heart rate and maximium/minimum heart rate was recorded using Holter monitoring.

Time frame:
Baseline, Month 6, Month 12
Reported as:
Mean · beats per minute (bpm)
24-Hour Average Heart Rate and Maximium/Minimum Heart Rate
beats per minute (bpm)Tafamidis
24-hour average heart rate: Baseline (n=34)74.7 ± 7.8
24-hour average heart rate: Month 6 (n=33)73.0 ± 7.2
24-hour average heart rate: Month 12 (n=30)76.6 ± 9.0
Maximum Heart Rate: Baseline (n=34)111.7 ± 22.3
Maximum Heart Rate: Month 6 (n=33)112.3 ± 17.0
Maximum Heart Rate: Month 12 (n=30)121.9 ± 20.4
Minimum Heart Rate: Baseline (n=34)56.6 ± 8.0
Minimum Heart Rate: Month 6: (n=33)53.1 ± 11.5
Minimum Heart Rate Month 12: (n=30)55.3 ± 10.1
Other pre-specifiedNumber of Participants With Complete Heart Block

Complete heart block is the third-degree atrioventricular block in which the impulse generated in the sinoatrial node in the atrium does not propagate to the ventricles.

Time frame:
Baseline, Month 6, Month 12

No measurements were reported for this outcome.

Other pre-specifiedHeart Rate Variability (HRV)- Standard Deviation (SD) Parameters

Holter monitor was a machine that recorded the heart rhythms. HRV time-domain indices were summarized for root-mean-square of successive differences \[RMS SD\] of the R-R intervals (R-R is the interval between successive Rs in the ECG wave) between normal beats (NN), magid standard deviation (Magid SD) of normal to normal R-R intervals and Kleiger standard deviation of normal to normal R-R intervals (Kleiger SD). The term 'NN' is used in place of 'R-R' when the processed beats are normal beats.

Time frame:
Baseline, Month 6, Month 12
Reported as:
Mean · msec
Heart Rate Variability (HRV)- Standard Deviation (SD) Parameters
msecTafamidis
HRV- RMS SD: Baseline (n=30)75.9 ± 71.0
HRV- RMS SD: Month 6 (n=26)88.1 ± 71.0
HRV- RMS SD: Month 12 (n=21)91.7 ± 72.1
HRV- Magid SD: Baseline (n=31)58.3 ± 42.1
HRV- Magid SD: Month 6 (n=33)82.6 ± 55.5
HRV- Magid SD: Month 12 (n=30)78.6 ± 50.1
HRV- Kleiger SD: Baseline (n=31)100.3 ± 49.1
HRV- Kleiger SD: Month 6 (n=33)123.9 ± 52.8
HRV- Kleiger SD: Month 12 (n=30)120.3 ± 48.7
Other pre-specifiedHeart Rate Variability- Percentage of Successive R-R Intervals With Greater Than 50 Msec Difference Between Normal Beats (pNN50)

Holter monitor was a machine that recorded the heart rhythms. The term 'NN' was used in place of 'R-R' when the processed beats are normal beats. The percentage of successive R-R intervals with greater than 50 msec difference between normal beats was derived by dividing NN50 by the total number of NN intervals (pNN50), where NN50 was the number of interval differences of successive NN intervals greater than 50 msec.

Time frame:
Baseline, Month 6, Month 12
Reported as:
Mean · Percentage of intervals
Heart Rate Variability- Percentage of Successive R-R Intervals With Greater Than 50 Msec Difference Between Normal Beats (pNN50)
Percentage of intervalsTafamidis
Baseline (n=30)19.7 ± 25.5
Month 6 (n=26)29.3 ± 32.7
Month 12 (n=21)23.6 ± 27.3
Other pre-specifiedNumber of Participants With Change From Baseline in New York Heart Association (NYHA) Classification at Week 6, Month 3, 6 and 12

NYHA: classified as 'class I' (participants with cardiac disease but without resulting limitations of physical activity), 'class II' (participants with cardiac disease resulting in slight limitation of physical activity), 'class III' (participants with cardiac disease resulting in marked limitation of physical activity), 'class IV' (participants with cardiac disease resulting in inability to carry on any physical activity without discomfort). Participants with change from baseline were classified as 'improved' (positive change), 'no change' or 'worsened' (negative change).

Time frame:
Baseline, Week 6, Month 3, Month 6, Month 12
Reported as:
Number · Participants
Number of Participants With Change From Baseline in New York Heart Association (NYHA) Classification at Week 6, Month 3, 6 and 12
ParticipantsTafamidis
Baseline: Class I (n=35)5
Baseline: Class II (n=35)28
Baseline: Class III (n=35)2
Baseline: Class IV (n=35)0
Change at Month 3: improved (n=34)5
Change at Month 3: no change (n=34)23
Change at Month 3: worsened (n=34)6
Change at Month 6: improved (n=34)1
Change at Month 6: no change (n=34)27
Change at Month 6: worsened (n=34)6
Change at Month 12: improved (n=32)4
Change at Month 12: no change (n=32)20
Change at Month 12: worsened (n=32)8
Other pre-specifiedCardiothoracic (CT) Ratio

Cardiothoracic ratio was defined as the transverse diameter of the heart, compared with that of the thoracic cage, used to help determine enlargement of the heart.

Time frame:
Baseline, Month 6, Month 12
Reported as:
Mean · Ratio
Cardiothoracic (CT) Ratio
RatioTafamidis
Baseline55.130 ± 6.075
Month 656.620 ± 5.904
Month 1257.830 ± 5.366
Other pre-specifiedNumber of Participants With Increased Interstitial Markings and Pleural Effusions

Chest x-ray was done to record the presence of increased interstitial markings (a large number of interstitial markings was indicative of abnormality in the lung) and pleural effusion, which was defined as accumulation of fluid between the layers of tissue that line the lungs and chest cavity.

Time frame:
Baseline, Month 6, Month 12
Reported as:
Number · Participants
Number of Participants With Increased Interstitial Markings and Pleural Effusions
ParticipantsTafamidis
Increased interstitial markings: Baseline11
Increased interstitial markings: Month 64
Increased interstitial markings: Month 124
Pleural effusion- right: Baseline9
Pleural effusion- right: Month 68
Pleural effusion- right: Month 126
Pleural effusion- left: Baseline6
Pleural effusion- left: Month 65
Pleural effusion- left: Month 124
Pleural effusion- bilateral: Baseline6
Pleural effusion- bilateral: Month 64
Pleural effusion- bilateral: Month 123
Other pre-specifiedNumber of Participants With Change in Patient Global Assessment (PtGA) at Month 3, 6 and 12

Participant's overall quality of life was measured by the PtGA. At baseline participants answered to question: "in general, how do you feel today?" - on a 5-point scale from '1' (excellent) to '5' (poor). At each follow-up visit, participant's answered to question: "How do you feel today as compared to when we talked with you at your last clinic visit for this study?" on a 7-point scale- '1' markedly improved, '2' moderately improved, '3' mildly improved, '4' unchanged, '5' mildly worsened, '6' moderately worsened, '7' markedly worsened.

Time frame:
Baseline, Month 3, Month 6, Month 12
Reported as:
Number · Participants
Number of Participants With Change in Patient Global Assessment (PtGA) at Month 3, 6 and 12
ParticipantsTafamidis
Excellent: Baseline (n=33)5
Very good: Baseline (n=33)14
Good: Baseline (n=33)12
Fair: Baseline (n=33)2
Poor: Baseline (n=33)0
Markedly improved: Month 3 (n=34)2
Moderately improved: Month 3 (n=34)7
Mildly improved: Month 3 (n=34)6
Unchanged: Month 3 (n=34)15
Mildly worsened: Month 3 (n=34)2
Moderately worsened: Month 3 (n=34)2
Markedly worsened: Month 3 (n=34)0
Markedly improved: Month 6 (n=34)3
Moderately improved: Month 6 (n=34)4
Mildly improved: Month 6 (n=34)3
Unchanged: Month 6 (n=34)16
Mildly worsened: Month 6 (n=34)8
Moderately worsened: Month 6 (n=34)0
Markedly worsened: Month 6 (n=34)0
Markedly improved: Month 12 (n=32)0
Moderately improved: Month 12 (n=32)5
Mildly improved: Month 12 (n=32)3
Unchanged: Month 12 (n=32)16
Mildly worsened: Month 12 (n=32)4
Moderately worsened: Month 12 (n=32)3
Markedly worsened: Month 12 (n=32)1
Other pre-specifiedChange From Baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) Score at Month 3, 6 and 12

KCCQ was a 23-item heart failure specific questionnaire quantified in to following 10 summary scores: physical limitation, symptom frequency, symptom severity, and symptom stability, total symptoms, quality of life, social interference, self-efficacy, overall summary and clinical summary. Total score ranged from 0 to 100, where higher scores indicated better functioning, fewer symptoms, and better disease specific quality of life. Summary scores were scaled to range from 0 to 100, with higher scores representing greater disability.

Time frame:
Baseline, Month 3, Month 6, Month 12
Reported as:
Mean · Units on a scale
Change From Baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) Score at Month 3, 6 and 12
Units on a scaleTafamidis
Physical limitations: Baseline (n=35)72.9 ± 20.8
Physical limitations: Change at Month 3 (n=33)-2.7 ± 15.0
Physical limitations: Change at Month 6 (n=34)-0.4 ± 13.6
Physical limitations: Change at Month 12 (n=31)-8.1 ± 18.8
Symptom stability: Baseline (n=35)55.7 ± 13.7
Symptom stability: Change at Month 3 (n=34)3.7 ± 27.6
Symptom stability: Change at Month 6 (n=34)-5.9 ± 25.4
Symptom stability: Change at Month 12 (n=31)0.0 ± 22.4
Symptom frequency: Baseline (n=35)73.8 ± 22.2
Symptom frequency: Change at Month 3 (n=34)-1.8 ± 18.5
Symptom frequency: Change at Month 6 (n=34)-2.5 ± 15.9
Symptom frequency: Change at Month 12 (n=31)-6.0 ± 18.2
Symptom burden: Baseline (n=35)76.9 ± 18.1
Symptom burden: Change at Month 3 (n=34)-4.0 ± 18.3
Symptom burden: Change at Month 6 (n=34)-4.7 ± 15.2
Symptom burden: Change at Month 12 (n=31)-8.6 ± 19.2
Total symptom: Baseline (n=35)75.4 ± 19.2
Total symptom: Change at Month 3 (n=34)-2.9 ± 16.9
Total symptom: Change at Month 6 (n=34)-3.6 ± 14.3
Total symptom: Change at Month 12 (n=31)-7.3 ± 18.2
Self-efficacy: Baseline (n=35)85.7 ± 19.0
Self-efficacy: Change at Month 3 (n=33)1.9 ± 14.7
Self-efficacy: Change at Month 6 (n=34)1.1 ± 13.5
Self-efficacy: Change at Month 12 (n=31)1.6 ± 16.7
Quality of life: Baseline (n=35)66.9 ± 19.2
Quality of life: Change at Month 3 (n=34)1.0 ± 18.2
Quality of life: Change at Month 6 (n=34)-0.2 ± 14.4
Quality of life: Change at Month 12 (n=31)-4.0 ± 20.4
Social limitation: Baseline (n=33)69.3 ± 25.4
Social limitation: Change at Month 3 (n=30)-0.6 ± 19.6
Social limitation: Change at Month 6 (n=31)-2.4 ± 22.6
Social limitation: Change at Month 12 (n=27)-9.2 ± 25.2
Overall summary: Baseline (n=35)71.4 ± 18.8
Overall summary: Change at Month 3 (n=34)-0.8 ± 14.9
Overall summary: Change at Month 6 (n=34)-1.5 ± 12.4
Overall summary: Change at Month 12 (n=31)-6.9 ± 18.0
Clinical summary: Baseline (n=35)74.1 ± 18.9
Clinical summary: Change at Month 3 (n=34)-2.0 ± 15.9
Clinical summary: Change at Month 6 (n=34)-2.0 ± 11.9
Clinical summary: Change at Month 12 (n=31)-7.7 ± 17.9
Other pre-specifiedChange From Baseline in the Short Form 36 (SF-36) at Month 3, 6 and 12

SF-36 was standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. Scores for the 8 domains range from 0-100, where higher scores were better (100=highest level of functioning) and reported as 2 summary scores; Mental Component Score (MCS) and Physical Component Score (PCS). The score for a section was an average of the individual question scores, which were scaled 0-100, where higher scores were better.

Time frame:
Baseline, Month 3, Month 6, Month 12
Reported as:
Mean · Units on a scale
Change From Baseline in the Short Form 36 (SF-36) at Month 3, 6 and 12
Units on a scaleTafamidis
PCS: Baseline (n=33)41.0 ± 9.69
PCS: Change at Month 6 (n=32)-1.4 ± 5.87
PCS: Change at Month 12 (n=29)-2.4 ± 7.58
MCS: Baseline (n=33)52.7 ± 9.51
MCS: Change at Month 6 (n=32)0.3 ± 8.40
MCS: Change at Month 12 (n=29)-2.0 ± 9.56
Physical functioning: Baseline (n=34)37.7 ± 11.28
Physical functioning: Change at Month 6 (n=33)-0.7 ± 6.89
Physical functioning: Change at Month 12 (n=29)-2.0 ± 7.34
Role-physical: Baseline (n=35)42.3 ± 10.84
Role-physical: Change at Month 6 (n=34)-1.4 ± 7.12
Role-physical: Change at Month 12 (n=30)-3.5 ± 9.29
Bodily pain: Baseline (n=35)53.2 ± 9.57
Bodily pain: Change at Month 6 (n=34)-4.0 ± 8.74
Bodily pain: Change at Month 12 (n=30)-3.2 ± 11.81
General health: Baseline (n=35)41.5 ± 9.33
General health: Change at Month 6 (n=34)0.7 ± 9.23
General health: Change at Month 12 (n=30)-1.6 ± 8.44
Vitality: Baseline (n=34)50.6 ± 8.11
Vitality: Change at Month 6 (n=33)-0.1 ± 6.83
Vitality: Change at Month 12 (n=30)-2.2 ± 7.83
Social functioning: Baseline (n=35)48.4 ± 9.84
Social functioning: Change at Month 6 (n=34)-2.9 ± 9.23
Social functioning: Change at Month 12 (n=30)-3.6 ± 11.40
Role-emotional: Baseline (n=35)45.2 ± 11.71
Role-emotional: Change at Month 6 (n=34)0.6 ± 12.26
Role-emotional: Change at Month 12 (n=30)-3.0 ± 12.53
Mental health: Baseline (n=34)53.3 ± 8.50
Mental health: Change at Month 6 (n=33)0.3 ± 5.01
Mental health: Change at Month 12 (n=30)-1.1 ± 7.50
Other pre-specifiedChange From Baseline in Troponin I and Troponin T at Week 2, 6, Month 3, 6 and 12

Troponin I and troponin T were the cardiac markers. Troponin I and troponin T were part of the troponin complex, where troponin I was bound to actin in thin myofilaments and troponin T was bound to tropomyosin. Higher level of these markers was indicative of heart damage.

Time frame:
Baseline, Week 2, Week 6, Month 3, Month 6, Month 12
Reported as:
Mean · nanogram/milliliter (ng/mL)
Change From Baseline in Troponin I and Troponin T at Week 2, 6, Month 3, 6 and 12
nanogram/milliliter (ng/mL)Tafamidis
Troponin I: Baseline (n=33)0.135 ± 0.080
Troponin I: Change at Week 2 (n=35)0.003 ± 0.060
Troponin I: Change at Week 6 (n=35)-0.000 ± 0.055
Troponin I: Change at Month 3 (n=34)0.008 ± 0.057
Troponin I: Change at Month 6 (n=34)-0.016 ± 0.051
Troponin I: Change at Month 12 (n=32)0.016 ± 0.064
Troponin T: Baseline (n=33)0.044 ± 0.037
Troponin T: Change at Week 2 (n=35)0.001 ± 0.025
Troponin T: Change at Week 6 (n=35)0.006 ± 0.020
Troponin T: Change at Month 3 (n=34)0.008 ± 0.021
Troponin T: Change at Month 6 (n=33)0.002 ± 0.020
Troponin T: Change at Month 12 (n=32)0.012 ± 0.023
Other pre-specifiedChange From Baseline in N-Terminal Prohormone Brain Natriuretic Peptide(NT-proBNP) Levels at Week 2, 6, Month 3, 6 and 12

NT-proBNP was a cardiac marker which had the prognostic value for participants with heart failure or left ventricular dysfunction. Higher level of the marker was indicative of heart damage.

Time frame:
Baseline, Week 2, Week 6, Month 3, Month 6, Month 12
Reported as:
Mean · picogram/mL (pg/mL)
Change From Baseline in N-Terminal Prohormone Brain Natriuretic Peptide(NT-proBNP) Levels at Week 2, 6, Month 3, 6 and 12
picogram/mL (pg/mL)Tafamidis
Baseline (n=33)4934.2 ± 4324.9
Change at Week 2 (n=35)-1.6 ± 1349.1
Change at Week 6 (n=35)295.0 ± 1632.0
Change at Month 3 (n=34)102.8 ± 1998.0
Change at Month 6 (n=33)111.6 ± 2032.4
Change at Month 12 (n=31)958.2 ± 3178.0
Other pre-specifiedChange From Baseline in 6-Minute Walk Test (6MWT) at Month 3, 6 and 12

6MWT was used to assess the distance that a participant could walk in 6 minutes. Participants were asked to perform the test at a pace that was comfortable to them, with as many breaks as they needed. Continuous pulse oximetry was conducted during the test for safety.. The distance walked in 6 minutes was categorized as: Level 1: \<300 meter, Level 2: 300-374.9 meter, Level 3: 375-449.9 meter, Level 4: \>=450 meter.

Time frame:
Baseline, Month 3, Month 6, Month 12
Reported as:
Mean · meters
Change From Baseline in 6-Minute Walk Test (6MWT) at Month 3, 6 and 12
metersTafamidis
Distance walked: Baseline (n=34)354.5 ± 126.0
Distance walked: Change at Month 3 (n=31)-4.6 ± 63.1
Distance walked: Change at Month 6 (n=33)3.9 ± 58.2
Distance walked: Change at Month 12 (n=28)-11.2 ± 76.4

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tafamidis—15/35 (42.9%)34/35 (97.1%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventTafamidis
Cardiac failure congestiveCardiac disorders9/35
Atrial fibrillationCardiac disorders3/35
FallInjury, poisoning and procedural complications3/35
Cardiac failureCardiac disorders2/35
SyncopeNervous system disorders2/35
Supraventricular tachycardiaCardiac disorders1/35
Ventricular tachycardiaCardiac disorders1/35
AmyloidosisImmune system disorders1/35
CellulitisInfections and infestations1/35
Escherichia sepsisInfections and infestations1/35
Most frequent other events
Showing 10 of 155
Most frequent other events
EventTafamidis
DyspnoeaRespiratory, thoracic and mediastinal disorders11/35
FatigueGeneral disorders8/35
DiarrhoeaGastrointestinal disorders7/35
DizzinessNervous system disorders7/35
Oedema peripheralGeneral disorders6/35
Upper respiratory tract infectionInfections and infestations6/35
Weight decreasedInvestigations6/35
Dizziness posturalNervous system disorders6/35
Dyspnoea exertionalRespiratory, thoracic and mediastinal disorders6/35
ConstipationGastrointestinal disorders5/35

Baseline characteristics

Age Continuous
Age Continuous(Years)Tafamidis
Mean76.4 ± 4.7
Sex: Female, Male
Sex: Female, Male(Participants)Tafamidis
Female3
Male32
08

Study locations

6 sites
  • Emory University School of Medicine
    Atlanta, Georgia 30322, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Johns Hopkins Hospital
    Baltimore, Maryland 21205, United States
  • Harvard Vanguard Medical Associates
    Boston, Massachusetts 02215, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Columbia University
    New York, New York 10032, United States
09

References and documents

Publications

  • Sultan MB, Gundapaneni B, Schumacher J, Schwartz JH. Treatment With Tafamidis Slows Disease Progression in Early-Stage Transthyretin Cardiomyopathy. Clin Med Insights Cardiol. 2017 Sep 18;11:1179546817730322. doi: 10.1177/1179546817730322. eCollection 2017. PubMed 28951660 ↗
  • Maurer MS, Grogan DR, Judge DP, Mundayat R, Packman J, Lombardo I, Quyyumi AA, Aarts J, Falk RH. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes. Circ Heart Fail. 2015 May;8(3):519-26. doi: 10.1161/CIRCHEARTFAILURE.113.000890. Epub 2015 Apr 14. PubMed 25872787 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2012, 2 years 11 months after primary completion. A results delay was requested in Oct 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2008
First posted
Jun 10, 2008
Start
Aug 2008
Primary completionActual
Jan 2010
CompletionActual
Jan 2010
Results delay requested
Oct 12, 2010
Results first posted
Dec 18, 2012
Last update
Jan 11, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00694161
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jun 10, 2008
Start date
Aug 2008
Primary completion
Jan 2010
Completion
Jan 2010
Results posted
Dec 18, 2012
Last update
Jan 11, 2013

Study contacts

Jeff Packman, MBA
study director · FoldRx Pharmaceuticals, Inc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tafamidis

Start the discussion